GILD — Gilead Sciences Cashflow Statement
0.000.00%
Last trade - 00:00
- $90.46bn
- $108.09bn
- $27.12bn
- 95
- 61
- 40
- 71
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 5,364 | 89 | 6,201 | 4,566 | 5,613 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 5,272 | 8,451 | 2,760 | 5,718 | 2,964 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -798 | -1,638 | 489 | -1,763 | -2,302 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 9,144 | 8,168 | 11,384 | 9,072 | 8,006 |
Capital Expenditures | -825 | -650 | -579 | -728 | -585 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -6,992 | -13,965 | -2,552 | -1,738 | -1,680 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -7,817 | -14,615 | -3,131 | -2,466 | -2,265 |
Financing Cash Flow Items | -122 | -138 | -145 | -173 | -278 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -7,634 | 770 | -8,877 | -6,469 | -5,125 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -6,309 | -5,634 | -659 | 74 | 673 |